ID   D35
AC   CVCL_DG37
SY   D35M1
DR   cancercelllines; CVCL_DG37
DR   Cosmic; 1996411
DR   GEO; GSM170590
DR   GEO; GSM218993
DR   GEO; GSM4178100
DR   Progenetix; CVCL_DG37
DR   Wikidata; Q54817218
RX   PubMed=17363583;
RX   PubMed=17516929;
RX   PubMed=22383533;
RX   PubMed=23039341;
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (PubMed=22383533).
CC   Omics: CNV analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 05-10-23; Version: 7
//
RX   PubMed=17363583; DOI=10.1158/0008-5472.CAN-06-4152;
RA   Stark M.S., Hayward N.K.;
RT   "Genome-wide loss of heterozygosity and copy number analysis in
RT   melanoma using high-density single-nucleotide polymorphism arrays.";
RL   Cancer Res. 67:2632-2642(2007).
//
RX   PubMed=17516929; DOI=10.1111/j.1600-0749.2007.00375.x;
RA   Johansson P., Pavey S., Hayward N.K.;
RT   "Confirmation of a BRAF mutation-associated gene expression signature
RT   in melanoma.";
RL   Pigment Cell Res. 20:216-221(2007).
//
RX   PubMed=22383533; DOI=10.1158/1535-7163.MCT-11-0676;
RA   Dutton-Regester K., Irwin D., Hunt P., Aoude L.G., Tembe V.,
RA   Pupo G.M., Lanagan C., Carter C.D., O'Connor L., O'Rourke M.,
RA   Scolyer R.A., Mann G.J., Schmidt C.W., Herington A., Hayward N.K.;
RT   "A high-throughput panel for identifying clinically relevant mutation
RT   profiles in melanoma.";
RL   Mol. Cancer Ther. 11:888-897(2012).
//
RX   PubMed=23039341; DOI=10.1186/1476-4598-11-75;
RA   Byron S.A., Loch D.C., Wellens C.L., Wortmann A., Wu J.-Y., Wang J.,
RA   Nomoto K., Pollock P.M.;
RT   "Sensitivity to the MEK inhibitor E6201 in melanoma cells is
RT   associated with mutant BRAF and wildtype PTEN status.";
RL   Mol. Cancer 11:75.1-75.15(2012).
//